Cerecor Inc. (CERC) EPS Estimated At $-0.10

July 14, 2018 - By Robert Reynolds

Cerecor Inc. (NASDAQ:CERC) Logo

Analysts expect Cerecor Inc. (NASDAQ:CERC) to report $-0.10 EPS on August, 13.They anticipate $0.04 EPS change or 28.57 % from last quarter’s $-0.14 EPS. After having $-0.07 EPS previously, Cerecor Inc.’s analysts see 42.86 % EPS growth. The stock decreased 8.22% or $0.37 during the last trading session, reaching $4.13. About 98,738 shares traded. Cerecor Inc. (NASDAQ:CERC) has risen 569.88% since July 14, 2017 and is uptrending. It has outperformed by 557.31% the S&P500.

Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. The company has market cap of $129.74 million. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder , as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. It has a 16.72 P/E ratio. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy.

More important recent Cerecor Inc. (NASDAQ:CERC) news were published by: Nasdaq.com which released: “Marina Biotech Appoints Robert Moscato to Chief Executive Officer” on June 20, 2018, also Streetinsider.com published article titled: “Form 8-K Marina Biotech, Inc. For: Jun 18”, Seekingalpha.com published: “Aptinyx IPO: It Collaborated With Allergan, But Shares Are Not Cheap” on June 27, 2018. More interesting news about Cerecor Inc. (NASDAQ:CERC) was released by: Globenewswire.com and their article: “Marina Biotech Appoints Uli Hacksell, Ph.D. and Robert C. Moscato to Board of Directors” with publication date: June 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.